Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection

Burden of enterotoxigenic Escherichia coli and shigella non-fatal diarrhoeal infections in 79 low-income and lower middle-income countries: a modelling analysis

(2019) John D Anderson et al.   Lancet Global Health

Consensus Report on Shigella Controlled Human Infection Model: Immunological Assays

(2019) Robert W Kaminski et al.   CLINICAL INFECTIOUS DISEASES

Consensus Report on Shigella Controlled Human Infection Model: Conduct of Studies

(2019) Kawsar R Talaat et al.   CLINICAL INFECTIOUS DISEASES

Consensus Report on Shigella Controlled Human Infection Model: Clinical Endpoints

(2019) Calman A MacLennan et al.   CLINICAL INFECTIOUS DISEASES

Antibiotic-Resistant Enteric Infections

(2019) Sadia Shakoor et al.   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Shigellosis

(2018) Karen L Kotloff et al.   LANCET

Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity score

(2018) Chad K. Porter et al.   PLoS One

Safety, tolerability and immunogenicity of the ExPEC4V (JNJ-63871860) vaccine for prevention of invasive extraintestinal pathogenic Escherichia coli disease: A phase 1, randomized, double-blind, placebo-controlled study in healthy Japanese participants

(2018) Megumi Inoue et al.   Human Vaccines & Immunotherapeutics

Use of quantitative molecular diagnostic methods to investigate the effect of enteropathogen infections on linear growth in children in low-resource settings: longitudinal analysis of results from the MAL-ED cohort study

(2018) Elizabeth T Rogawski et al.   Lancet Global Health

Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial

(2017) Angela Huttner et al.   LANCET INFECTIOUS DISEASES

Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study

(2016) Mark S. Riddle et al.   Clinical and Vaccine Immunology

Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial

(2016) Ligia A. Pinto et al.   JOURNAL OF INFECTIOUS DISEASES

Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study

(2016) Jie Liu et al.   LANCET

Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study

(2015) Christoph F.R Hatz et al.   VACCINE

Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED)

(2015) James A Platts-Mills et al.   Lancet Global Health

Effects of Shigella-, Campylobacter- and ETEC-associated Diarrhea on Childhood Growth

(2014) Gwenyth Lee et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

The Shigella human challenge model

(2012) C. K. PORTER et al.   EPIDEMIOLOGY AND INFECTION

Salivary Immune Responses to the 7-Valent Pneumococcal Conjugate Vaccine in the First 2 Years of Life

(2012) Gerwin D. Rodenburg et al.   PLoS One

Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1–4-year-old Israeli children

(2010) Justen H. Passwell et al.   VACCINE

Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidates

(2008) J.K. Simon et al.   VACCINE